Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VRNA |
---|---|---|
09:32 ET | 9761 | 30.81 |
09:34 ET | 368 | 30.86 |
09:36 ET | 2672 | 30.935 |
09:38 ET | 2851 | 31.0864 |
09:39 ET | 2607 | 31.19 |
09:41 ET | 5285 | 31.2516 |
09:43 ET | 4713 | 31.3529 |
09:45 ET | 9100 | 31.65 |
09:48 ET | 9215 | 31.705 |
09:50 ET | 9752 | 31.9439 |
09:52 ET | 5060 | 31.96 |
09:54 ET | 13689 | 31.92 |
09:56 ET | 1677 | 31.8906 |
09:57 ET | 11560 | 31.86 |
09:59 ET | 4458 | 31.63 |
10:01 ET | 14081 | 31.69 |
10:03 ET | 13387 | 31.6751 |
10:06 ET | 22387 | 31.99 |
10:08 ET | 4527 | 32.1 |
10:10 ET | 3766 | 32.0762 |
10:12 ET | 8245 | 32.24 |
10:14 ET | 35882 | 32.14 |
10:15 ET | 25831 | 32.67 |
10:17 ET | 1699 | 32.38 |
10:19 ET | 1200 | 32.46 |
10:21 ET | 3600 | 32.71 |
10:24 ET | 4578 | 32.515 |
10:26 ET | 5015 | 32.525 |
10:28 ET | 14223 | 32.46 |
10:30 ET | 7758 | 32.365 |
10:32 ET | 2606 | 32.475 |
10:33 ET | 1946 | 32.38 |
10:35 ET | 2288 | 32.4 |
10:37 ET | 4222 | 32.405 |
10:39 ET | 2984 | 32.235 |
10:42 ET | 1507 | 32.32 |
10:44 ET | 1159 | 32.31 |
10:46 ET | 900 | 32.2 |
10:48 ET | 500 | 32.315 |
10:50 ET | 200 | 32.39 |
10:51 ET | 2052 | 32.436 |
10:53 ET | 4475 | 32.34 |
10:55 ET | 2506 | 32.475 |
10:57 ET | 207 | 32.43 |
11:00 ET | 900 | 32.43 |
11:02 ET | 2817 | 32.57 |
11:04 ET | 1059 | 32.525 |
11:06 ET | 3911 | 32.51 |
11:08 ET | 1800 | 32.55 |
11:09 ET | 100 | 32.44 |
11:11 ET | 850 | 32.5294 |
11:13 ET | 2361 | 32.5383 |
11:15 ET | 400 | 32.535 |
11:18 ET | 600 | 32.5752 |
11:20 ET | 1188 | 32.55 |
11:22 ET | 12103 | 32.54 |
11:24 ET | 4990 | 32.545 |
11:26 ET | 6646 | 32.62 |
11:27 ET | 792 | 32.6053 |
11:29 ET | 4029 | 32.575 |
11:31 ET | 5847 | 32.635 |
11:33 ET | 750 | 32.635 |
11:36 ET | 23316 | 32.43 |
11:38 ET | 748 | 32.38 |
11:40 ET | 600 | 32.32 |
11:42 ET | 1100 | 32.455 |
11:44 ET | 3717 | 32.3101 |
11:45 ET | 1150 | 32.315 |
11:47 ET | 100 | 32.315 |
11:49 ET | 600 | 32.4 |
11:51 ET | 1534 | 32.325 |
11:54 ET | 7116 | 32.39 |
11:56 ET | 3628 | 32.48 |
11:58 ET | 1200 | 32.415 |
12:00 ET | 340 | 32.415 |
12:02 ET | 4900 | 32.5 |
12:03 ET | 20757 | 32.73 |
12:05 ET | 1320 | 32.74 |
12:07 ET | 2368 | 32.66 |
12:09 ET | 1100 | 32.8092 |
12:12 ET | 1711 | 32.635 |
12:14 ET | 300 | 32.61 |
12:16 ET | 4412 | 32.5846 |
12:18 ET | 2800 | 32.5417 |
12:20 ET | 1201 | 32.5044 |
12:21 ET | 990 | 32.465 |
12:23 ET | 880 | 32.55 |
12:25 ET | 972 | 32.51 |
12:27 ET | 1100 | 32.56 |
12:30 ET | 500 | 32.505 |
12:32 ET | 2472 | 32.4732 |
12:34 ET | 1111 | 32.4 |
12:36 ET | 3289 | 32.305 |
12:38 ET | 2306 | 32.3 |
12:39 ET | 3119 | 32.39 |
12:41 ET | 1000 | 32.36 |
12:43 ET | 7155 | 32.245 |
12:45 ET | 4354 | 32.22 |
12:48 ET | 1150 | 32.2088 |
12:50 ET | 1565 | 32.1 |
12:52 ET | 800 | 32.14 |
12:54 ET | 6700 | 32.2049 |
12:56 ET | 2038 | 32.071 |
12:57 ET | 1200 | 32.025 |
12:59 ET | 3328 | 32.13 |
01:01 ET | 584 | 32.09 |
01:03 ET | 388 | 32.07 |
01:06 ET | 580 | 32.125 |
01:08 ET | 200 | 32.08 |
01:10 ET | 700 | 32.185 |
01:12 ET | 2200 | 32.25 |
01:14 ET | 400 | 32.275 |
01:15 ET | 300 | 32.335 |
01:17 ET | 2809 | 32.45 |
01:19 ET | 3954 | 32.45 |
01:21 ET | 2880 | 32.4 |
01:24 ET | 2234 | 32.41 |
01:26 ET | 1200 | 32.43 |
01:28 ET | 3235 | 32.46 |
01:30 ET | 598 | 32.475 |
01:32 ET | 2598 | 32.255 |
01:33 ET | 600 | 32.35 |
01:35 ET | 1993 | 32.4 |
01:37 ET | 2799 | 32.345 |
01:39 ET | 1050 | 32.43 |
01:42 ET | 2686 | 32.46 |
01:44 ET | 200 | 32.47 |
01:46 ET | 750 | 32.475 |
01:48 ET | 5123 | 32.49 |
01:50 ET | 850 | 32.43 |
01:51 ET | 1500 | 32.444 |
01:53 ET | 1100 | 32.305 |
01:55 ET | 200 | 32.31 |
01:57 ET | 775 | 32.37 |
02:00 ET | 2800 | 32.38 |
02:02 ET | 2469 | 32.5 |
02:04 ET | 2140 | 32.455 |
02:06 ET | 3202 | 32.475 |
02:08 ET | 2088 | 32.48 |
02:09 ET | 6154 | 32.49 |
02:11 ET | 15540 | 32.43 |
02:13 ET | 3674 | 32.29 |
02:15 ET | 1343 | 32.275 |
02:18 ET | 4094 | 32.45 |
02:20 ET | 1400 | 32.47 |
02:22 ET | 18337 | 32.52 |
02:24 ET | 3146 | 32.71 |
02:26 ET | 3914 | 32.605 |
02:27 ET | 600 | 32.536 |
02:29 ET | 1350 | 32.605 |
02:31 ET | 400 | 32.53 |
02:33 ET | 3870 | 32.5 |
02:36 ET | 54705 | 32.485 |
02:38 ET | 2162 | 32.515 |
02:40 ET | 5656 | 32.505 |
02:42 ET | 4300 | 32.395 |
02:44 ET | 400 | 32.39 |
02:45 ET | 1080 | 32.46 |
02:47 ET | 15589 | 32.39 |
02:49 ET | 900 | 32.46 |
02:51 ET | 400 | 32.385 |
02:54 ET | 1222 | 32.43 |
02:56 ET | 2300 | 32.415 |
02:58 ET | 1558 | 32.39 |
03:00 ET | 2306 | 32.47 |
03:02 ET | 900 | 32.475 |
03:03 ET | 800 | 32.48 |
03:05 ET | 3500 | 32.4 |
03:07 ET | 2308 | 32.385 |
03:09 ET | 4348 | 32.45 |
03:12 ET | 700 | 32.46 |
03:14 ET | 1811 | 32.4 |
03:16 ET | 2801 | 32.41 |
03:18 ET | 1117 | 32.36 |
03:20 ET | 5552 | 32.355 |
03:21 ET | 1201 | 32.48 |
03:23 ET | 9161 | 32.2 |
03:25 ET | 7009 | 32.11 |
03:27 ET | 3879 | 32.225 |
03:30 ET | 4459 | 32.2 |
03:32 ET | 4100 | 32.09 |
03:34 ET | 4706 | 32.25 |
03:36 ET | 2744 | 32.26 |
03:38 ET | 3212 | 32.3141 |
03:39 ET | 3332 | 32.2899 |
03:41 ET | 3090 | 32.24 |
03:43 ET | 21119 | 32.03 |
03:45 ET | 9988 | 32.04 |
03:48 ET | 3347 | 32.07 |
03:50 ET | 7000 | 32.08 |
03:52 ET | 22420 | 31.9201 |
03:54 ET | 8174 | 31.9 |
03:56 ET | 18536 | 31.8 |
03:57 ET | 26646 | 32.025 |
03:59 ET | 65164 | 32.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Verona Pharma PLC | 2.6B | -20.6x | --- |
Geron Corp | 2.6B | -12.0x | --- |
Edgewise Therapeutics Inc | 2.7B | -18.5x | --- |
Structure Therapeutics Inc | 2.5B | -19.2x | --- |
CG Oncology Inc | 2.5B | -31.4x | --- |
SpringWorks Therapeutics Inc | 2.4B | -7.4x | --- |
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-1.55 |
Book Value | $3.10 |
P/E Ratio | -20.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.